These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 37372349)

  • 1. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer.
    Greco L; Rubbino F; Dal Buono A; Laghi L
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
    Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of microsatellite instability in colorectal cancer: A review.
    Gelsomino F; Barbolini M; Spallanzani A; Pugliese G; Cascinu S
    Cancer Treat Rev; 2016 Dec; 51():19-26. PubMed ID: 27838401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 19. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer.
    Yeh YS; Tsai HL; Chen PJ; Chen YC; Su WC; Chang TK; Huang CW; Wang JY
    Expert Rev Mol Diagn; 2023 Mar; 23(3):231-241. PubMed ID: 36908268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. License to kill: microsatellite instability and immune contexture.
    Maby P; Bindea G; Mlecnik B; Galon J
    Oncoimmunology; 2021 Apr; 10(1):1905935. PubMed ID: 33868790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.